[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100561681":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":18,"centralContacts":25,"locations":34,"responsibleParty":51,"collaborators":55,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":65,"eligibilityCriteria":66,"healthyVolunteers":61,"sex":67,"minAge":18,"maxAge":18,"enrollmentInfo":68,"targetDuration":18,"studyType":71,"phases":72,"briefSummary":74,"conditions":75,"keywords":80,"overallStatus":36,"whyStopped":18,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"University of Texas Southwestern Medical Center","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Risk Assessment and Intensive Prevention Strategy","EXPERIMENTAL","Primary care providers (PCP) randomized to the Risk Assessment and Intensive Prevention Strategy Arm will receive notification if any patients with diabetes under their care have high heart failure risk based on clinical or biomarker scores. Providers will receive recommendations, option for e-consultation, and referral to cardiometabolic risk management program.",[13],"Behavioral: Intensive Prevention Strategy",{"label":15,"type":16,"description":17,"interventionNames":18},"Usual Care","NO_INTERVENTION","Primary care providers randomized to the Usual care arm will not receive any notifications about patients with diabetes and their HF risk assessment.",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":18},"BEHAVIORAL","Intensive Prevention Strategy","Providers randomized to the intensive prevention strategy will receive notification about patients with diabetes who have high heart failure risk and recommendations for medical management, e-consultation, or referral to a cardiometabolic risk management program.",[9],[26,31],{"name":27,"role":28,"phone":29,"phoneExt":18,"email":30},"Ambarish Pandey, MD","CONTACT","617-869-8957","ambarish.pandey@utsouthwestern.edu",{"name":32,"role":28,"phone":33,"phoneExt":18,"email":18},"VINAYAK SUBRAMANIAN, MD","2114-645-9868",[35],{"facility":5,"status":36,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"RECRUITING","Dallas","Texas","75209","United States","US",{"type":43,"coordinates":44},"Point",[45,46],-96.80667,32.78306,{"lat":46,"lon":45},[49],{"name":27,"role":28,"phone":50,"phoneExt":18,"email":30},"214-645-9868",{"type":52,"investigatorFullName":53,"investigatorTitle":54,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"PRINCIPAL_INVESTIGATOR","Ambarish Pandey","Associate Professor of Internal Medicine",[56],{"name":57,"class":58},"Roche Diagnostics GmbH","INDUSTRY","100561681","nt-probnp-based-heart-failure-screening-and-prevention-trial-in-patients-with-type-2-diabetes-strong-dm-study-100561681",false,"NCT06593327","NT-ProBNP-based Heart Failure Screening and Prevention Trial in Patients With Type 2 Diabetes: STRONG-DM Study","Evaluation of a Pragmatic NT-ProBNP-based Heart Failure Screening Strategy Among Patients With Type 2 Diabetes: STRONG-DM Study (Screening and Treatment Using Risk-based apprOach With NT-ProBNP Guidance in Diabetes Mellitus","STRONG-DM","Inclusion Criteria:\n\n* Primary Care Provider that sees diabetes patients in clinic\n\nExclusion Criteria:\n\n* Provider does not see patients with Diabetes","ALL",{"count":69,"type":70},300,"ESTIMATED","INTERVENTIONAL",[73],"NA","A pragmatic, randomized clinical trial to evaluate the effect of a heart failure (HF) risk assessment and prevention strategy incorporating HF clinical risk scores (WATCH-DM) with cardiac biomarker (NT-proBNP) paired with a clinical decision support tool to implement an intensive prevention strategy among patients with high risk focused on implementation of evidence-based HF preventive therapies.",[76,77,78,79],"Type 2 Diabetes","Diabetic Cardiomyopathy","Heart Failure","Cardiometabolic Diseases",[81,78,82],"Pragmatic Clinical Trial","Cardiovascular Prevention","2026-02-26",{"date":85,"type":86},"2026-02-27","ACTUAL",{"date":88,"type":86},"2025-02-10",{"date":90,"type":70},"2027-12-15",{"name":5,"class":6},1]